Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brooke Caldwell

Nurse Practitioner, Adult Health Dallas, TX Nurse Practitioner

NPI 1043785744 CMS profile 10952244

10260 N Central Expy 100N, Dallas, TX 75231

Open in the dashboard

General payments

$2,347

93 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brooke Caldwell of Dallas, TX is reported in the CMS Open Payments database as having received $2,347 across 93 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $291 4
2024 General $393 5
2023 General $104 2
2022 General $732 41
2021 General $828 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brooke Caldwell
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Brooke Caldwell were reported at $291. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Brooke Caldwell Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $828 $138 $43–$438 $132
2022 $732 $165 $54–$494 $149
2023 $104 $178 $61–$549 $160
2024 $393 $186 $62–$575 $164
2025 $291 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. TG Therapeutics, Inc. $247 2 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $234 9 payments
  3. Amgen Inc. $230 11 payments
  4. AstraZeneca Pharmaceuticals LP $162 10 payments
  5. GlaxoSmithKline, LLC. $132 1 payment
  6. Amarin Pharma Inc. $127 8 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $119 1 payment
  8. AbbVie, Inc. $93 5 payments
  9. Argenx US, Inc. $92 1 payment
  10. Horizon Therapeutics plc $89 1 payment
  11. Other $822 44 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,341 92 payments
  2. Education $7 1 payment
Products named General payments · program years 2021–2025
  1. BRIUMVI $247 2 payments
  2. Kerendia $234 9 payments
  3. Prolia $215 10 payments
  4. FARXIGA $137 9 payments
  5. BENLYSTA $132 1 payment
  6. Vascepa $127 8 payments
  7. ENTYVIO $119 1 payment
  8. EVENITY $102 9 payments
  9. SYNTHROID $93 5 payments
  10. VYVGART $92 1 payment
  11. Other $1,166 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$2,069,922

Of which drugs: $2,032,168

Medicare patients

349

Average age 75

Services billed

138,024

242 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Osteoporosis 49%
Ischemic heart disease 34%
Depression 29%
Chronic kidney disease 28%
Diabetes 27%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tildrakizumab, 1 mg J3245 Office 17 3,500 $376,616
Injection, denosumab, 1 mg J0897 Office 111 8,220 $169,559
Injection, inclisiran, 1 mg J1306 Office 21 7,668 $73,111
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 14 1,290 $32,072
Injection, omalizumab, 5 mg J2357 Office 11 750 $22,900
Injection, ertapenem sodium, 500 mg J1335 Office 27 300 $2,679
Injection, daptomycin, 1 mg J0878 Office 14 53,000 $1,988

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BENLYSTA
  • GlaxoSmithKline, LLC. $132
$132 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $119
$119 — —
BRIUMVI
  • TG Therapeutics, Inc. $110
$110 — —
KRYSTEXXA
  • Amgen Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

93 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record